FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016185162> ?p ?o ?g. }

• W2016185162 endingPage "795" @default.
• W2016185162 startingPage "784" @default.
• W2016185162 abstract "ObjectiveMultiple myeloma remains incurable with current therapy. The proteosome inhibitor, PS-341, has shown objective clinical responses in relapsed refractory myeloma patients. We investigated the potential of enhancing the radiosensitivity of myeloma cells by combining with PS-341; the underlying mechanisms were delineated.Materials and MethodsClonogenic assays were used to evaluate cell survival after exposure to PS-341, ionizing radiation (IR), or PS-341 followed by IR. Apoptosis was studied by annexin V-propidium iodide staining and caspase activation. Cell-cycle phase distribution of cells was determined. Nuclear factor-κB (NF-κB) activity was monitored by enzyme-linked immunosorbent assay and Western blotting. The expression of death receptor Fas/APO-1/CD95 was analyzed by flow cytometry. The consequential caspase-8 activation was detected by Western blotting.ResultsIn clonogenic assays, sequential exposure to nontoxic doses of PS-341 (10 nM) and IR (6 Gy) resulted in synergistic inhibition of proliferation of myeloma cells by modulating the apoptotic sensitivity of these cells. Biochemically, sublethal dose of IR led to potent induction of NF-κB activity, and this response was significantly inhibited by pretreatment with PS-341, or by the NF-κB inhibitory peptide SN-50. Enhanced Fas expression was seen in myeloma cells exposed sequentially to PS-341 and IR. Finally, PS-341 sensitized primary myeloma (CD138+ve) cells to IR but had little effect on CD138-ve bone marrow cells from myeloma patients.ConclusionThese data indicate that PS-341 can sensitize myeloma cells to IR by both intrinsic and extrinsic apoptotic pathways. The study indicates improved therapeutic benefits in treatment of multiple myeloma by combining PS-341 with conventional radiotherapy. Multiple myeloma remains incurable with current therapy. The proteosome inhibitor, PS-341, has shown objective clinical responses in relapsed refractory myeloma patients. We investigated the potential of enhancing the radiosensitivity of myeloma cells by combining with PS-341; the underlying mechanisms were delineated. Clonogenic assays were used to evaluate cell survival after exposure to PS-341, ionizing radiation (IR), or PS-341 followed by IR. Apoptosis was studied by annexin V-propidium iodide staining and caspase activation. Cell-cycle phase distribution of cells was determined. Nuclear factor-κB (NF-κB) activity was monitored by enzyme-linked immunosorbent assay and Western blotting. The expression of death receptor Fas/APO-1/CD95 was analyzed by flow cytometry. The consequential caspase-8 activation was detected by Western blotting. In clonogenic assays, sequential exposure to nontoxic doses of PS-341 (10 nM) and IR (6 Gy) resulted in synergistic inhibition of proliferation of myeloma cells by modulating the apoptotic sensitivity of these cells. Biochemically, sublethal dose of IR led to potent induction of NF-κB activity, and this response was significantly inhibited by pretreatment with PS-341, or by the NF-κB inhibitory peptide SN-50. Enhanced Fas expression was seen in myeloma cells exposed sequentially to PS-341 and IR. Finally, PS-341 sensitized primary myeloma (CD138+ve) cells to IR but had little effect on CD138-ve bone marrow cells from myeloma patients. These data indicate that PS-341 can sensitize myeloma cells to IR by both intrinsic and extrinsic apoptotic pathways. The study indicates improved therapeutic benefits in treatment of multiple myeloma by combining PS-341 with conventional radiotherapy." @default.
• W2016185162 created "2016-06-24" @default.
• W2016185162 creator A5000308170 @default.
• W2016185162 creator A5002846184 @default.
• W2016185162 creator A5004152557 @default.
• W2016185162 creator A5039057642 @default.
• W2016185162 creator A5051470930 @default.
• W2016185162 creator A5072775789 @default.
• W2016185162 date "2005-07-01" @default.
• W2016185162 modified "2023-09-23" @default.
• W2016185162 title "PS-341–mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis" @default.
• W2016185162 cites W1759028523 @default.
• W2016185162 cites W1969294339 @default.
• W2016185162 cites W1972931253 @default.
• W2016185162 cites W1973792489 @default.
• W2016185162 cites W1976186736 @default.
• W2016185162 cites W1977348505 @default.
• W2016185162 cites W1980471295 @default.
• W2016185162 cites W1984041107 @default.
• W2016185162 cites W1988257437 @default.
• W2016185162 cites W1990175178 @default.
• W2016185162 cites W1995975133 @default.
• W2016185162 cites W1996591735 @default.
• W2016185162 cites W2007689766 @default.
• W2016185162 cites W2022135873 @default.
• W2016185162 cites W2022638530 @default.
• W2016185162 cites W2025433329 @default.
• W2016185162 cites W2026158949 @default.
• W2016185162 cites W2028851768 @default.
• W2016185162 cites W2032330155 @default.
• W2016185162 cites W2038237282 @default.
• W2016185162 cites W2039722337 @default.
• W2016185162 cites W2044964025 @default.
• W2016185162 cites W2045927984 @default.
• W2016185162 cites W2047447041 @default.
• W2016185162 cites W2048188560 @default.
• W2016185162 cites W2051840229 @default.
• W2016185162 cites W2051994734 @default.
• W2016185162 cites W2053102794 @default.
• W2016185162 cites W2058680827 @default.
• W2016185162 cites W2070739194 @default.
• W2016185162 cites W2070756073 @default.
• W2016185162 cites W2073922677 @default.
• W2016185162 cites W2077945404 @default.
• W2016185162 cites W2078581194 @default.
• W2016185162 cites W2081510209 @default.
• W2016185162 cites W2090653170 @default.
• W2016185162 cites W2108235071 @default.
• W2016185162 cites W2120755323 @default.
• W2016185162 cites W2121500163 @default.
• W2016185162 cites W2127143739 @default.
• W2016185162 cites W2144063202 @default.
• W2016185162 cites W2146502962 @default.
• W2016185162 cites W2147921405 @default.
• W2016185162 cites W2152065071 @default.
• W2016185162 cites W2154745425 @default.
• W2016185162 cites W2154932260 @default.
• W2016185162 cites W2169295136 @default.
• W2016185162 cites W2292093022 @default.
• W2016185162 cites W2330374913 @default.
• W2016185162 cites W2335735158 @default.
• W2016185162 cites W2416374603 @default.
• W2016185162 cites W4211256216 @default.
• W2016185162 cites W4256726715 @default.
• W2016185162 doi "https://doi.org/10.1016/j.exphem.2005.04.005" @default.
• W2016185162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15963854" @default.
• W2016185162 hasPublicationYear "2005" @default.
• W2016185162 type Work @default.
• W2016185162 sameAs 2016185162 @default.
• W2016185162 citedByCount "63" @default.
• W2016185162 countsByYear W20161851622012 @default.
• W2016185162 countsByYear W20161851622013 @default.
• W2016185162 countsByYear W20161851622014 @default.
• W2016185162 countsByYear W20161851622015 @default.
• W2016185162 countsByYear W20161851622016 @default.
• W2016185162 countsByYear W20161851622017 @default.
• W2016185162 countsByYear W20161851622019 @default.
• W2016185162 countsByYear W20161851622022 @default.
• W2016185162 crossrefType "journal-article" @default.
• W2016185162 hasAuthorship W2016185162A5000308170 @default.
• W2016185162 hasAuthorship W2016185162A5002846184 @default.
• W2016185162 hasAuthorship W2016185162A5004152557 @default.
• W2016185162 hasAuthorship W2016185162A5039057642 @default.
• W2016185162 hasAuthorship W2016185162A5051470930 @default.
• W2016185162 hasAuthorship W2016185162A5072775789 @default.
• W2016185162 hasBestOaLocation W20161851621 @default.
• W2016185162 hasConcept C104317684 @default.
• W2016185162 hasConcept C117262875 @default.
• W2016185162 hasConcept C153911025 @default.
• W2016185162 hasConcept C185592680 @default.
• W2016185162 hasConcept C190283241 @default.
• W2016185162 hasConcept C203014093 @default.
• W2016185162 hasConcept C2775934118 @default.
• W2016185162 hasConcept C2776364478 @default.
• W2016185162 hasConcept C2777478702 @default.
• W2016185162 hasConcept C31573885 @default.
• W2016185162 hasConcept C502942594 @default.
• W2016185162 hasConcept C553184892 @default.

• next